@article{ff36ad0780b34f02a5f9e29ae2a85a02,
title = "Redefining the role of biomarkers in heart failure trials: expert consensus document",
abstract = "Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.",
keywords = "Biomarker, Clinical trial, Drug development, Heart failure, Imaging, Medical device",
author = "Frank Kramer and Sabbah, {Hani N.} and Januzzi, {James J.} and Faiez Zannad and {Peter van Tintelen}, J. and Schelbert, {Erik B.} and Kim, {Raymond J.} and Hendrik Milting and Richardus Vonk and Brien Neudeck and Richard Clark and Klaus Witte and Wilfried Dinh and Burkert Pieske and Javed Butler and Mihai Gheorghiade",
note = "Funding Information: M.G. received grant support from AbbVie Inc., AstraZeneca, Bayer Pharma AG, Cardiocell LLC, Cardiorentis Ltd., GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Pharmaceuticals USA, Otsuka Pharmaceuticals, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Stealth BioTherapeutics, Sticares InterACT, and Takeda Pharmaceuticals North America Inc. Funding Information: J.J. received grant support from Siemens, Singulex, and Prevencio and consulting income from Roche Diagnostics, Critical Diagnostics, Sphingotec, Bayer, Philips, and Novartis and participates in clinical endpoint committees/data safety monitoring boards for Novartis, Amgen, Janssen, and Boehringer Ingelheim and is supported in part by the Hutter Family Professorship Endowment in Cardiology at the Harvard Medical School. Funding Information: J.B. received research support from the National Institutes of Health, European Union, and Patient Centered Outcomes Research Institute and is a consultant to Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, BMS, CVRx, Janssen, Medtronic, Novartis, Relypsa, and ZS Pharma. Funding Information: H.M. supported by the Deutsche Forschungsgemeinschaft (DFG), the Deutsches Zentrum f{\"u}r Herz-Kreislauferkrankungen (DZHK), and the Erich & Hanna Klessmann-Foundation, Germany, and received fees and research funding from the Bayer AG, Germany. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",
year = "2017",
month = may,
day = "1",
doi = "10.1007/s10741-017-9608-5",
language = "English (US)",
volume = "22",
pages = "263--277",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "3",
}
